ArticleOncotarget2021

Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab.

Ilyas Sahin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.